Board service is often described in formal terms. Governance. Oversight. Fiduciary duty. Yet for founders navigating the volatility of biotech, the boardroom is rarely an abstract space. It is where scientific ambition meets capital discipline, where risk becomes visible, and where leadership is tested under conditions that allow little margin for error. Leen Kawas approaches this environment with a perspective shaped by having sat on both sides of the table.
As the CEO of EIT Pharma, a board member at Inherent Biosciences, and the co-founder and managing general partner of Propel Bio Partners, Kawas brings operational memory into governance. She is not advising from theory. She is drawing on lived experience as a founder who built and led a biotech company through late-stage clinical development and a public offering. That experience informs how she supports other founders without displacing their authority.
Kawas’s boardroom posture begins with respect for the founder’s role. She has emphasized, in paraphrased reflections, that founders carry a form of contextual knowledge that cannot be replicated. They understand the science’s origin story, the early trade-offs, and the invisible constraints that shaped the company’s trajectory. Effective board support, in her view, does not override that knowledge. It sharpens it by asking the right questions at the right moments.
One of the ways Kawas supports founders is by normalizing the difficulty of biotech leadership. Clinical development unfolds over years, often with ambiguous signals and high burn rates. Boards that react reflexively to volatility can undermine long-term strategy. Kawas brings steadiness to these conversations, grounding decisions in data while acknowledging uncertainty. This balance helps founders think clearly when external pressure intensifies.
Her scientific background plays a central role here. Kawas is fluent in the language of discovery and development. She can interrogate clinical strategy without reducing it to financial abstraction. This fluency allows her to act as a translator between scientific teams and capital markets. Founders benefit when their boards understand not just timelines and milestones, but the underlying biology driving them. It reduces misalignment and builds trust.
Kawas also supports founders by being explicit about trade-offs. She has resisted the tendency to frame board guidance as neutral or consequence-free. Every decision closes some doors and opens others. By naming those realities, she helps founders retain agency. They are not being managed toward a predetermined outcome. They are being supported in making informed choices that align with their vision and the company’s constraints.
Her experience taking a company public informs this approach. Navigating investors, regulators, and public scrutiny requires a different rhythm than early-stage building. Kawas understands how quickly narratives can outpace fundamentals. In the boardroom, she has helped founders anticipate these shifts without becoming captive to them. The goal is not to perform confidence, but to build it through preparation and coherence.
As a venture fund leader, Leen Kawas also brings a portfolio-level perspective. She sees patterns across companies, stages, and therapeutic areas. This vantage point allows her to offer context without comparison. She avoids imposing templates. Instead, she surfaces lessons that may be relevant and lets founders decide how to apply them. This restraint preserves founder ownership while expanding their field of vision.
Another dimension of her boardroom support is timing. Kawas has emphasized that good advice delivered too early or too late can be ineffective. Founders are often inundated with opinions. Knowing when to intervene and when to observe requires attunement. Kawas listens carefully before engaging, ensuring that her contributions land when they can be integrated rather than defended against.
There is also an emotional intelligence to this work that is rarely discussed openly. Biotech leadership can be isolating. High-stakes decisions are often made under confidentiality, limiting external support. Kawas understands this isolation firsthand. In the boardroom, she creates space for candor without theatrics. Founders are more likely to surface concerns when they feel they will be met with seriousness rather than judgment.
Importantly, Kawas does not conflate support with protection. She is direct when expectations are not met or when strategy requires recalibration. Her credibility allows for this directness. Founders trust feedback when it is grounded in shared accountability. Support, in this framing, means being willing to engage hard questions rather than avoiding them.
Her role across multiple boards and leadership positions reinforces a consistent philosophy. Governance works best when it is relational without becoming personal. Kawas maintains clear boundaries while remaining deeply invested in outcomes. This balance helps founders feel accompanied rather than supervised.
There is a broader implication to Kawas’s approach. Biotech boards shape not only company outcomes, but founder development. Leaders carry these experiences forward into future ventures, boards, and ecosystems. By modeling thoughtful, founder-centered governance, Kawas contributes to a culture that values durability over spectacle.
How Leen Kawas supports founders from the boardroom is not defined by a single tactic. It is defined by presence, fluency, and restraint. She brings the memory of building, the discipline of science, and the perspective of capital into a space where all three must coexist. For founders navigating uncertainty, that combination offers something rare. Not direction, but partnership in thinking through what comes next.
Learn more about Leen Kawas in her interview with Principal Post: